{
"id":"mk19_bb_on_s1",
"subspecialtyId":"on",
"title":"Breast Cancer",
"jsonContent":{
"type":"section",
"id":"mk19_bb_on_s1",
"title":{
"__html":"Breast Cancer"
},
"titleNode":{
"type":"section-title",
"hlId":"a6e49f",
"children":[
"Breast Cancer"
]
},
"children":[
{
"type":"section",
"id":"mk19_bb_on_s1_1",
"title":{
"__html":"Screening and Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"4b0eb9",
"children":[
"Screening and Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"6b6e26",
"children":[
"See General Internal Medicine, Breast Cancer Prevention and Screening."
]
},
{
"type":"p",
"hlId":"14614d",
"children":[
"The ",
{
"type":"abbreviation",
"title":"U.S. Preventive Services Task Force",
"children":[
"USPSTF"
]
},
" recommends biennial screening mammography for asymptomatic average-risk women aged 50 to 74 years, with individualized screening decisions for patients aged 40 to 49 years. For women ≥75 years, evidence is insufficient to recommend for or against screening."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_on_s1_2",
"title":{
"__html":"Testing"
},
"titleNode":{
"type":"section-title",
"hlId":"fa6a5a",
"children":[
"Testing"
]
},
"children":[
{
"type":"p",
"hlId":"675dd8",
"children":[
"See General Internal Medicine, Breast Mass for evaluation of a breast lump."
]
},
{
"type":"p",
"hlId":"7c15e1",
"children":[
"Schedule biopsy for suspicious lesions noted during physical examination or screening mammography. If histopathologic studies confirm invasive breast cancer, determine ",
{
"type":"abbreviation",
"title":"estrogen receptor",
"children":[
"ER"
]
},
"/",
{
"type":"abbreviation",
"title":"progesterone receptor",
"children":[
"PR"
]
},
" and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2/neu"
]
},
" status."
]
},
{
"type":"p",
"hlId":"fa2d0f",
"children":[
"The two factors that are most prognostic are tumor size and axillary lymph node status."
]
},
{
"type":"p",
"hlId":"567f81",
"children":[
"Bone scan, CT, or ",
{
"type":"abbreviation",
"title":"positron emission tomography",
"children":[
"PET"
]
},
" scan is recommended for patients with stage III disease or clinically evident metastatic disease."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"c5e610",
"children":[
"A normal mammogram or ultrasound does not rule out breast cancer."
]
},
" ",
{
"type":"list-item",
"hlId":"ec0b09",
"children":[
"A breast lump should always be biopsied, even if a mammogram is normal."
]
},
" ",
{
"type":"list-item",
"hlId":"f1a73a",
"children":[
"Bone scan, CT, PET scan, and tumor marker tests are not routine studies for staging ",
{
"type":"abbreviation",
"title":"ductal carcinoma in situ",
"children":[
"DCIS"
]
},
" (stage 0) or early-stage (I and II) breast cancer."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_on_s1_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"b65f13",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"DCIS"
]
},
" is treated with wide excision followed by radiation or with mastectomy if the tumor cannot be completely removed by excision. ER-positive tumors are treated with tamoxifen (premenopausal women only) or aromatase inhibitors. Surgery and endocrine therapy decrease the risk for recurrence and contralateral breast cancer but not survival. Follow-up includes annual mammography and clinical evaluation for 5 years."
]
},
{
"type":"p",
"hlId":"d7bdb0",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Invasive breast cancer"
]
},
" is usually treated with excision (lumpectomy), radiation, and adjuvant systemic therapy. Mastectomy is appropriate for patients with inflammatory breast cancer; cancer involving the skin, chest wall, or more than one quadrant of the breast; or contraindications to radiation therapy (previous irradiation). Bilateral mastectomy is an option for women with familial breast cancer syndromes."
]
},
{
"type":"p",
"hlId":"67bed9",
"children":[
"In patients with clinically negative axillary lymph nodes, a sentinel biopsy is performed. Axillary lymph node dissection is performed if sentinel lymph node biopsy is positive or axillary lymph nodes are clinically involved."
]
},
{
"type":"p",
"hlId":"1c5ca8",
"children":[
"Chest wall radiation therapy after mastectomy is recommended in patients with tumors >5 cm, positive surgical margins, skin or chest wall involvement, or inflammatory breast cancer, and for most patients with ≥4 positive axillary nodes. Postmastectomy radiation increases overall survival."
]
},
{
"type":"p",
"hlId":"0d4786",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Paget disease of the breast"
]
},
" is characterized by a scaly or red rash or ulceration occurring on the nipple and spreading to the areola. It is usually associated with an underlying ductal breast carcinoma and is diagnosed with skin biopsy."
]
},
{
"type":"p",
"hlId":"b5ef07",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Inflammatory breast cancer"
]
},
" is an aggressive and rapidly progressive type of cancer characterized by erythema and edema of the skin of the breast (“peau d’orange”). It is often mistaken for infectious mastitis. Inflammatory breast cancer is treated with neoadjuvant chemotherapy, followed by surgery, and then radiation."
]
},
{
"type":"p",
"hlId":"37376d",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Adjuvant hormone therapy"
]
},
" for ER/PR-positive nonmetastatic breast cancer is used to prevent or delay systemic recurrence for stages I to III invasive breast cancer and is associated with increased overall survival."
]
},
{
"type":"p",
"hlId":"829805",
"children":[
"In premenopausal women, a 5- to 10-year course of adjuvant tamoxifen is recommended. Premenopausal women who previously completed 5 years of tamoxifen may benefit from taking an aromatase inhibitor for 5 years when they become postmenopausal."
]
},
{
"type":"p",
"hlId":"f60ee1",
"children":[
"Postmenopausal women are treated with 5 years of an aromatase inhibitor (anastrozole, letrozole, exemestane) or 2 years of tamoxifen and 3 years of an aromatase inhibitor."
]
},
{
"type":"p",
"hlId":"847396",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Adjuvant chemotherapy"
]
},
" is primarily indicated for patients with hormone receptor–negative (triple-negative) tumors, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
"-positive tumors, or positive lymph nodes. Neoadjuvant chemotherapy, given before surgery, is recommended for some tumors to determine effectiveness of systemic therapy or to downstage disease to allow for less extensive surgical resection. It is also used in patients with inflammatory and locally advanced cancers."
]
},
{
"type":"p",
"hlId":"9bc865",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Molecular prognostic profiles"
]
},
", such as the 21-gene recurrence score, which can be used in ER/PR-positive and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
"-negative tumors, help determine the benefit of adjuvant chemotherapy. Patients with high-risk recurrence scores will benefit from adjuvant chemotherapy followed by antiestrogen therapy, whereas those with low-risk scores do not benefit from adjuvant chemotherapy."
]
},
{
"type":"p",
"hlId":"fb2765",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
"-positive breast cancer"
]
},
" is treated with adjuvant trastuzumab and/or pertuzumab along with chemotherapy. Patients should undergo evaluation of ",
{
"type":"abbreviation",
"title":"left ventricular",
"children":[
"LV"
]
},
" function before initiating and during trastuzumab treatment."
]
},
{
"type":"p",
"hlId":"f6a595",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Metastatic breast cancer"
]
},
" that is hormone receptor positive can be treated with antiestrogen therapy. In ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2-"
]
},
"positive metastatic breast cancer, treatment with trastuzumab, chemotherapy, or antiestrogen therapy is guided by hormone receptor status. Patients who have hormone receptor–negative disease or who do not respond to antiestrogen therapy are treated with chemotherapy. In patients with ",
{
"type":"abbreviation",
"title":"breast cancer susceptibility gene",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA"
]
}
]
},
" mutations, poly (ADP-ribose) polymerase (PARP) inhibitors (olaparib, talazoparib) improve progression-free survival relative to chemotherapy."
]
},
{
"type":"p",
"hlId":"d0aba7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Lytic bone metastases"
]
},
" are treated with bisphosphonates to decrease bone pain and skeletal-related events. The monoclonal antibody denosumab is an alternate option. Painful skeletal disease is treated with radiation therapy."
]
}
]
},
{
"type":"section",
"id":"mk19_bb_on_s1_4",
"title":{
"__html":"Follow-up"
},
"titleNode":{
"type":"section-title",
"hlId":"b9c20d",
"children":[
"Follow-up"
]
},
"children":[
{
"type":"p",
"hlId":"b26313",
"children":[
"Patients with early-stage breast cancer should receive annual mammography. MRI of the breast is reserved for patients who have an especially high risk for subsequent breast cancer from ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"BRCA1/2"
]
},
" mutations or a strong family history of breast cancer. Surveillance blood tests and other imaging studies are not recommended."
]
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"824210",
"children":[
"Aromatase inhibitors are contraindicated in premenopausal women."
]
},
" ",
{
"type":"list-item",
"hlId":"aab506",
"children":[
"Ovarian ablation or suppression can be used for premenopausal women with contraindications to tamoxifen."
]
},
" ",
{
"type":"list-item",
"hlId":"8feb2d",
"children":[
"Do not select mastectomy in patients with metastatic disease unless required for local cancer control."
]
},
" ",
{
"type":"list-item",
"hlId":"9f63d6",
"children":[
"Pregnancy following breast cancer treatment does not increase the risk for breast cancer recurrence."
]
},
" "
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_bb_on_s1_inline_t1"
],
"forceOpen":true
},
{
"type":"heading",
"class":"tricked",
"children":[
"Don't Be Tricked"
]
},
{
"type":"list",
"class":"tricked",
"children":[
" ",
{
"type":"list-item",
"hlId":"f725d0",
"children":[
"Biopsy new metastatic lesions; primary tumor and metastatic tumor ER and ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
" status differs in up to 15% of patients."
]
},
" "
]
}
]
},
{
"type":"section",
"id":"mk19_bb_on_s1_5",
"title":{
"__html":"Test Yourself"
},
"titleNode":{
"type":"section-title",
"hlId":"7866cc",
"children":[
"Test Yourself"
]
},
"children":[
{
"type":"p",
"hlId":"22436a",
"class":"test",
"children":[
"A 50-year-old premenopausal woman has a 1.5-cm moderately differentiated breast cancer. The lesion is completely excised (lumpectomy), and the surgical margins are negative. Three axillary lymph nodes are positive. The tumor is negative for ER and PR and highly positive for ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2/neu"
]
},
"."
]
},
{
"type":"p",
"hlId":"45916c",
"class":"test_answer",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Answer:"
]
},
" ",
"For diagnosis, choose stage III ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"HER2"
]
},
"-positive, hormone receptor–negative breast cancer. For management, select postoperative radiation therapy, adjuvant chemotherapy, and trastuzumab and/or pertuzumab, but not tamoxifen or aromatase inhibitors."
]
}
]
}
]
},
"tablesContent":{
"mk19_bb_on_s1_inline_t1":{
"id":"mk19_bb_on_s1_inline_t1",
"number":1,
"bookId":"on",
"title":{
"__html":"Study Table: Breast Cancer Treatment Side Effects"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b32f41",
"children":[
"Study Table: Breast Cancer Treatment Side Effects"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c485c1",
"class":"col hd l",
"children":[
"Side Effect"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"932ca7",
"class":"cell txt l",
"children":[
"Aromatase inhibitors (anastrazole, letrozole, exemestane)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2d907",
"class":"cell txt l",
"children":[
"Arthralgia, bone pain, hyperlipidemia, osteoporosis (",
{
"type":"abbreviation",
"title":"dual-energy x-ray absorptiometry",
"children":[
"DEXA"
]
},
" scan every 2 years; treat with bisphosphonate if T-score <−2.5)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc465c",
"class":"cell txt l",
"children":[
"Tamoxifen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"286a7d",
"class":"cell txt l",
"children":[
"Endometrial cancer, ",
{
"type":"abbreviation",
"title":"venous thromboembolism",
"children":[
"VTE"
]
},
" disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75c43b",
"class":"cell txt l",
"children":[
"Anthracyclines (doxorubicin, epirubicin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"beca02",
"class":"cell txt l",
"children":[
"Cardiomyopathy, acute leukemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c0c51",
"class":"cell txt l",
"children":[
"Trastuzumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da49b7",
"class":"cell txt l",
"children":[
"Cardiomyopathy, especially if used with an anthracycline (measure ",
{
"type":"abbreviation",
"title":"left ventricular ejection fraction",
"children":[
"LVEF"
]
},
" before initiation)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9e152",
"class":"cell txt l",
"children":[
"Bisphosphonates"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"066663",
"class":"cell txt l",
"children":[
"Osteonecrosis of the jaw, particularly in patients with dental disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9208da",
"class":"cell txt l",
"children":[
"Denosumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a23b1",
"class":"cell txt l",
"children":[
"Hypocalcemia and osteonecrosis of the jaw, particularly in patients with dental disease"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}